Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of PBI-200 in Healthy Volunteers
NCT05160389Phase 1Completed
- Sponsor
- Pyramid Biosciences
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paltimatrectinib in NTRK fusion-positive solid tumors (3 arms), sponsored by Pyramid Biosciences. Primary endpoints: Time to Maximum Concentration at 7 days, Area Under the Concentration-Time Curve from time zero to last measurable concentration at 7 days and 1 more. Started Nov 2021; status: completed.
02
Drugs
paltimatrectinib
03
Conditions
NTRK fusion-positive solid tumors
Beyond the preview
Go deeper on NCT05160389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160389.